TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35274092
Drug: Low-dose azathioprine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azathioprine (median dose 50 mg) combined with allopurinol (100 mg)
Study: 35274092
Drug: Azathioprine monotherapy
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine monotherapy (median dose 200 mg)
Study: 32444401
Drug: As-needed budesonide-formoterol
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed budesonide-formoterol (200/6 μg Turbuhaler, one actuation)
Study: 32444401
Drug: Maintenance budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations)
Study: 36905485
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100
Study: 32462206
Drug: Placebo moisturizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo moisturizer applied twice daily for 12 weeks
Study: 33278832
Drug: Warfarin (GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (GFR ≥ 45–59)
Study: 33278832
Drug: Warfarin (GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (GFR < 45)
Study: 33278832
Drug: Warfarin (ARISTOTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (ARISTOTLE and ENGAGE trials, GFR ≥ 45–59)
Study: 33278832
Drug: Warfarin (ARISTOTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (ARISTOTLE and ENGAGE trials, GFR < 45)
Study: 33085861
Drug: AK002 (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK002 (combined low-dose and high-dose)
Study: 39284383
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy
Study: 34004416
Drug: ResistAid (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ResistAid (15 g/d)
Study: 36336861
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high oral dose of vitamin D3 (120,000 IU)
Study: 33805193
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) applied to 15 patients (17 elbows)
Study: 33805193
Drug: Rest-and-medication group
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest-and-medication group (RMG) with 15 patients
Study: 32978204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no specific foot intervention and following treatment recommended by the medical team
Study: 36914957
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin)
Study: 32926760
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment
Study: 35419799
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL normal saline)
Study: 33988725
Drug: Tradipitant 85
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tradipitant 85 mg/bid
Study: 33988725
Drug: Oxycodone (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0 to 30 mg)
Study: 32565318
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate radiation therapy (NHT arm)
Study: 32565318
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy (CAHT arm)
Study: 36625789
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate
Study: 34419676
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT)
Study: 33185380
Drug: Aspirin-treated group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-treated group
Study: 33142541
Drug: Organic zinc
Normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic zinc (zinc amino acid complex) at low (35 mg/kg) and high (70 mg/kg) levels
Study: 33142541
Drug: Inorganic zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic zinc (zinc sulfate) at low (35 mg/kg) and high (70 mg/kg) levels
Study: 32644104
Drug: Fluorouracil-based adjuvant
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based adjuvant chemotherapy
Study: 34949506
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline, 20 mL) administered intravenously
Study: 34462287
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin or carboplatin plus pemetrexed)
Study: 33072620
Drug: L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine treatment
Study: 36195164
Drug: Intraurethral prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral prilocaine solution
Study: 36195164
Drug: Intraurethral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral lidocaine gel
Study: 33706573
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy / Mindfulness Based Stress Reduction intervention
Study: 34213493
Drug: Intrathecal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal buprenorphine (0.5 mL, 60 mg) with 3 mL of heavy (0.5%) hyperbaric bupivacaine
Study: 34384597
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (NSS 20 mL before skin incision and at 3 hours after surgery)
Study: 34384597
Drug: One-dose (1D)
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose (1D) group (750 mg TXA before skin incision and NSS 20 mL at 3 hours after surgery)
Study: 34384597
Drug: Two-dose (2D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose (2D) group (750 mg TXA before skin incision and 750 mg TXA at 3 hours after surgery)
Study: 32216814
Drug: GSK3008348 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008348 (1000 mcg nebulised dose)
Study: 32867986
Drug: Standard BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BW treatment with 12L:12D rearing photoschedule
Study: 38715179
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg
Study: 33408531
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose complex (ISC)
Study: 32220771
Drug: Mannitol plus
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol plus hypertonic saline combination (MHS)
Study: 32220771
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline monotherapy (HS)
Study: 34811841
Drug: Basic Body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Body Awareness Therapy (BBAT)
Study: 32753750
Drug: Cooling therapy
Normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate COOLING THERAPY TWIST UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling therapy
Study: 32173802
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg 30 minutes before induction
Study: 32734238
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution
Study: 33406277
Drug: ACT-1004-1239 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1004-1239 (doses 1-200 mg)
Study: 33051029
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy (ICBT) delivered in research settings
Study: 33051029
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy (ICBT) delivered in community settings
Study: 34269720
Drug: Dexamethasone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (16 mg) and 20% albumin (100 mL) at induction of anesthesia, then 200 mL of 20% albumin with each subsequent 1000 mL of crystalloid administered (Dex‐Alb group)
Study: 33416500
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS treatment
Study: 35877195
Drug: Favipiravir tablet
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir tablet (200 mg)
Study: 39620432
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy
Study: 33462582
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g orally once weekly for 3 weeks
Study: 33462582
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for 21 days
Study: 36036087
Drug: Low-dose vonoprazan-amoxicillin
Normalized name: vonoprazan, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose vonoprazan-amoxicillin dual therapy (amoxicillin 1 g b.i.d. for 7 or 10 days, vonoprazan 20 mg b.i.d.)
Study: 37025023
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg
Study: 33176205
Drug: Meningococcal Conjugate
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal Conjugate Vaccine (MCV-A) and control vaccine (inactivated polio vaccine)
Study: 32273234
Drug: Docetaxel chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy
Study: 35544387
Drug: Subcutaneous lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenacapavir every 6 months with optimized background therapy (Cohort 2)
Study: 37833651
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment
Study: 33226999
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor
Study: 33226999
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor vs. Non-nucleoside reverse transcriptase inhibitor
Study: 34872717
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (ferric carboxymaltose 1000 mg i.v.)
Study: 34210290
Drug: Continue anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue anti-PD-1 treatment until disease progression/unacceptable toxicity/for at least 2 years in the absence of disease progression/unacceptable toxicity
Study: 34210290
Drug: Stop treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop treatment
Study: 34210290
Drug: Continue anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue anti-PD-1 treatment
Study: 32969024
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for patients arriving between 6 and 24 hours with ASPECTS ≥7
Study: 32969024
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for patients arriving between 0 and 6 hours
Study: 33047329
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day)
Study: 34463311
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS)
Study: 32025589
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.05%
Study: 35403447
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg/day tablet
Study: 35403447
Drug: Cabozantinib 140
Normalized name: cabozantinib 140 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 140 mg/day capsules
Study: 34289471
Drug: High UFNET
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High UFNET rate (>1.75 mL/kg/h)
Study: 34289471
Drug: Middle UFNET
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle UFNET rate (1.01‐1.75 mL/kg/h)
Study: 34289471
Drug: Low UFNET
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low UFNET rate (<1.01 mL/kg/h)
Study: 34289471
Drug: Every 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 1.0 mL/kg/h increase in UFNET rate
Study: 34289471
Drug: UFNET rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFNET rates >1.75 mL/kg/h compared with rates 1.01‐1.75 and <1.01 mL/kg/h
Study: 37349841
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg
Study: 36912792
Drug: Steroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injections
Study: 35354635
Drug: GelStix nucleus
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GelStix nucleus augmentation device
Study: 35747962
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus 80 mg/day nano-curcumin capsules
Study: 33882590
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin
Study: 32028085
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound (FUS) treatment
Study: 35168840
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about COVID-19 vaccine development and mistrust in vaccines
Study: 32779057
Drug: SZC 5
Normalized name: Sildenafil citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SZC 5 g
Study: 32779057
Drug: SZC 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SZC 10 g
Study: 32886337
Drug: Vehicle lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle lotion (control)
Study: 33826709
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 or 300 mg
Study: 34448273
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (Tacrolimus and Mycophenolate mofetil)
Study: 33991996
Drug: Esketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 0.25 mg/kg
Study: 35255530
Drug: Esketamine 1
Normalized name: esketamine 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 1 mg/kg
Study: 38526550
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine
Study: 32940090
Drug: Tuberculosis vaccine
Normalized name: Tuberculosis vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis vaccine
Study: 32940090
Drug: SARS-CoV-2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccines (various candidates)
Study: 32669145
Drug: Clozapine and
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine and paliperidone palmitate combination therapy
Study: 34373315
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo
Study: 34183702
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600-1800 mg
Study: 39652807
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT)
Study: 34503349
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily along with 9 cycles of CyBorD
Study: 35261932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sitagliptin + spironolactone)
Study: 33632377
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1000 mg ferric carboxymaltose)
Study: 34477963
Drug: Refrigerated 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerated 2% lignocaine HCl with 1:100,000 epinephrine (LE) after topical ice application for 15 seconds
Study: 34477963
Drug: Conventional LE
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional LE infiltration after topical gel application for 1 minute
Study: 32516227
Drug: 0-Mo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-Mo (placebo and morphine)
Study: 36178335
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg once daily (q.d.)
Study: 36178335
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (q.d.)
Study: 34936739
Drug: Spesolimab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab (900 mg intravenous dose)
Study: 33153401
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (enoxaparin)
Study: 35437957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FQs with cephalosporins/macrolides for 1 month
Study: 32750571
Drug: Heparin lead-in
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin lead-in
Study: 36347845
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg)
Study: 35353979
Drug: Ivermectin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400 µg per kilogram of body weight) once daily for 3 days
Study: 35311524
Drug: NTM-1633 (0.033,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1633 (0.033, 0.165, or 0.330 mg/kg)
Study: 35311524
Drug: NTM-1633 (0.330
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1633 (0.330 mg/kg)
Study: 32144522
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg kg-1 IV‐TXA and 20 mg IV‐DXM
Study: 35970494
Drug: Standard micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard micronutrient supplement (control)
Study: 34844929
Drug: Intra‐articular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular saline injections
Study: 34190419
Drug: FDC formulation
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC formulation of bazedoxifene 20 mg and cholecalciferol 8 mg
Study: 34190419
Drug: Individual component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual component tablets of bazedoxifene and cholecalciferol
Study: 35404638
Drug: Moral reconation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moral reconation therapy (MRT)
Study: 35404638
Drug: Moral reconation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moral reconation therapy (MRT) (per-protocol analysis)
Study: 35780325
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 IU of vitamin D3 monthly for 5 years)
Study: 34225200
Drug: Heat stress
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heat stress + ADP group (HSA, basal diet supplemented with 1,000 mg/kg ADP)
Study: 35549802
Drug: Thrombopoietin mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin mimetic peptide 0.3 μg/kg
Study: 35549802
Drug: Thrombopoietin mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin mimetic peptide 1.0 μg/kg
Study: 36123934
Drug: ISU303 (Agalsidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISU303 (Agalsidase beta), 1 mg/kg dose administered every other week for 6 months
Study: 34706171
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Itepekimab plus Dupilumab)
Study: 34684511
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status above 75 nmol/L
Study: 34787590
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST)
Study: 33939666
Drug: Low-dose Auxora
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Auxora plus standard of care (SOC)
Study: 32720832
Drug: Probiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bifidobacterium lactis Bi‐07, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM) with conventional treatment
Study: 32720832
Drug: Probiotics with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics with conventional treatment
Study: 32345378
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg
Study: 32732928
Drug: RCA‐ALSS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCA‐ALSS therapy with R‐CA model
Study: 32732928
Drug: RCA‐ALSS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCA‐ALSS therapy with R‐CA score
Study: 32732928
Drug: RCA‐ALSS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCA‐ALSS therapy with R‐CA score of 0-2